AnaptysBio Announces Third Quarter 2018 Financial Results and Provides Pipeline Updates

Go back to AnaptysBio Announces Third Quarter 2018 Financial Results and Provides Pipeline Updates

AnaptysBio (ANAB) PT Lowered to $146 at Wedbush

November 9, 2018 10:46 AM EST

Wedbush analyst David Nierengarten lowered the price target on AnaptysBio (NASDAQ: ANAB) to $146.00 (from $147.00) while maintaining a Outperform rating.

... More